title: The impact of uterine re-curettage, pre-evacuation and week-one level of hCG on the number of chemotherapy courses in treatment of post molar GTN.
abstract: BACKGROUND
  Post molar GTN was reported to occur in 7.5-20% of patients following evacuation of complete hydatidiform moles and in 2.5-7.5% following evacuation of partial moles. The role of uterine re-curettage in post molar GTN is not clear.
  
  
  OBJECTIVE
  Study of the correlation of pre-evacuation and week- one level of hCG, and uterine re-curettage to the number of chemotherapy courses in treatment of post molar GTN.
  
  
  METHODS
  This retrospective study included 29 cases of post molar GTN through reviewing their medical records.
  
  
  RESULTS
  There were 25 cases (86.21) of low risk, and 4 cases of high risk score (13.79%). The 3 year survival was 96.6%. There were non-significant correlation of age, parity, pre-evacuation level and hCG in week-1 to number of chemotherapy courses, while uterine re-curettage was significantly correlated to number of chemotherapy courses (p = 0.04).
  
  
  CONCLUSIONS
  Uterine re-curettage was significantly correlated to less number of chemotherapy courses in patients with post molar GTN (p = 0.04). Pre-evacuation and week-1 hCG were not correlated to number of chemotherapy cycles. A large prospective randomized trial to clarify the beneficial effect of uterine re-curettage is recommended.
authors: Department of Obstetrics and Gynaecology, Mansoura University Hospital, Egypt. redaelshouky@yahoo.com
authors: Reda A
authors: RA
authors: Hemida
authors: Eman
authors: E
authors: Toson
authors: H C
authors: HC
authors: Van Doorn
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D006063:Chorionic Gonadotropin / Q000097:blood*; D002945:Cisplatin / Q000008:administration & dosage; D004107:Dilatation and Curettage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011247:Pregnancy; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D004317:Doxorubicin; D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate